ClinicalTrials.gg
CompletedNCT03001011RECOVERUpdated Mar 25, 2022Results posted

Evaluation of Renvela in Patients With Chronic Kidney Disease Not On Dialysis And Hyperphosphatemia In China

A Phase 3 interventional study of Placebo and Sevelamer Carbonate (GZ419831) in Hyperphosphatemia, sponsored by Sanofi. Completed at 38 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-03-25.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
202
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 12 studies testing sevelamer in Hyperphosphatemia — none open to participants now, none under way, none of them phase 3. Sevelamer · Hyperphosphatemia.

Enrollment
3rd of 12
202 · median 45
Started
2017
with 2 others
Phase 3
5 of 12
none open now
Registered
10th of 12
by date
Lead sponsor
1 of 12
Sanofi

Among the 12 studies testing sevelamer in Hyperphosphatemia, this one is the 3rd largest by enrollment, is one of 3 that started in 2017, is one of 5 in phase 3, and was the 10th registered.

Hyperphosphatemia

173 studies on the registry are indexed under Hyperphosphatemia; 16 are open to participants now.

Browse Hyperphosphatemia studies →

Open to participants now

None of the 12 studies testing sevelamer in Hyperphosphatemia is open now. The open studies under Hyperphosphatemia, anywhere →

About sevelamer

Sevelamer: first FDA approval 1998 (RENAGEL), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 13 Hyperphosphatemia studies recruiting now, 11 (85%) set no upper age limit and 2 (15%) stop at 75 or younger; 4 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies testing sevelamer in Hyperphosphatemia as a file.
02

Study summary

Primary Objective:

To demonstrate efficacy of Renvela tablets in the reduction of serum phosphorus in hyperphosphatemia in participants with chronic kidney disease not on dialysis.

Secondary Objectives:

To document the efficacy of Renvela tablets in the reduction of serum lipids (total cholesterol and low-density lipoprotein cholesterol [LDL-C]).

To document the efficacy of Renvela tablets in the reduction of calcium-phosphorus product.

To document the efficacy of Renvela tablets in the reduction of intact parathyroid hormone (iPTH).

To document the efficacy of Renvela tablets in proportion of participants reaching the target serum phosphorus level 4.6 milligrams per decilitre (mg/dL) (1.47 millimoles per litre [mmol/L], inclusive).

To evaluate safety of Renvela tablets.

Read the detailed description

The total duration of study period per participant was up to 14 weeks.

03

Conditions studied

  • Hyperphosphatemia

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with chronic kidney disease who had not been on dialysis, and were not expected to begin dialysis, or renal transplantation in the next 4 months from the screening visit.
  • Had serum phosphorus measurement greater than or equal to (>=) 5.5 mg/dL (1.78 mmol/L) at screening visit (if participants were not on phosphate binder[s] at Screening Visit) OR at the end of (if participants were on phosphate binder[s] at screening visit).
  • Had the following laboratory measurements at screening visit:

    • 25-hydroxy vitamin D >=10 nanograms per milliliter (ng/mL).
    • intact parathyroid hormone, intact parathyroid hormone (iPTH) \<=800 picograms per millilitre (pg/mL).
    • Signed written .

Exclusion criteria

Exclusion criteria:

  • Men or women below 18 years of age.
  • Any technical/administrative reason that made it impossible to randomize the participant in the study.
  • Was not of the level of understanding and willingness to cooperate with all visits and procedures, as described in the study protocol.
  • Not yet received chronic kidney disease diet education before screening visit.
  • Not willing and not able to avoid changes to diet during the study.
  • Not willing or able to maintain screening doses of lipid lowering medication, 1, 25 dihydroxy vitamin D, and/or cinacalcet for the duration of the study, except for safety reasons.
  • Not willing or not able to avoid antacids and phosphate binders containing aluminium, magnesium, calcium, or lanthanum for the duration of the study unless prescribed as an evening calcium supplement.
  • Had participated in any other drug studies within 30 days, or 5 half lives, whichever is longer, prior to screening visit.
  • Conditions/situations such as:

    • Participant was the Investigator or any Subinvestigator, research assistant, pharmacist, study coordinator, other staff or relative thereof directly involved in the conduct of the protocol.
    • Uncooperative or any condition that could make the participant potentially non-compliant to the study procedures (for example, participants could not be contacted by phones as required in phone call visits).
    • Evidence of active .
    • Not on stable medical condition (for example, but not limited to, active ethanol or drug abuse [tobacco use acceptable]; documented poorly controlled diabetes mellitus, poorly controlled hypertension, active vasculitis, [HIV] infection), or had any medical conditions.
  • Had known to sevelamer or any constituents of Renvela tablets.
  • Had bowel obstruction, active dysphagia or swallowing disorder, or a predisposition to or current bowel obstruction, ileus, or severe gastrointestinal motility disorders including severe constipation.
  • Using or plan to use anti-arrhythmic or anti-seizure medications for arrhythmia or seizure disorders.
  • Was pregnant or breast-feeding.
  • If the participant was female, and of (pre-menopausal and not surgically sterile), was not willing to use an effective method throughout the study.
  • Had any condition, which in the opinion of the investigator would prohibit the participant's inclusion in the study.

The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
202 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Participants received placebo (for Renvela) orally 3 times per day (TID) for up to 8 weeks. One to five tablets were taken with meals, as directed by physician and were titrated (up to a maximum of 15 tablets per day) to reach a target goal of serum phosphorus less than or equal to (\<=) 4.6 mg/dL (\<=1.49 mmol/L).

    Drug: Placebo

  • Experimental
    Renvela

    Participants received Renvela orally TID for up to 8 weeks. One to five tablets were taken with meals, as directed by physician and were titrated (up to a maximum of 15 tablets per day) to reach a target goal of serum phosphorus \<=4.6 mg/dL (\<=1.49 mmol/L).

    Drug: Sevelamer Carbonate (GZ419831)

Interventions

  • DrugPlacebo

    Pharmaceutical form: tablet Route of administration: oral

  • Pharmaceutical form: tablet Route of administration: oral

    Also known as: Renvela

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Serum Phosphorus at Week 8

    Baseline of serum phosphorus value was the last serum phosphorus level obtained before the first double-blind investigational medicinal product (IMP) dosing. Missing Week 8 data were imputed by last observation carried forward \[LOCF\] method.

    Time frame: Baseline, Week 8

Secondary outcomes

  1. Change From Baseline in Total Cholesterol at Week 8

    Missing Week 8 data were imputed by LOCF method.

    Time frame: Baseline, Week 8

  2. Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 8

    Missing Week 8 data were imputed by LOCF method.

    Time frame: Baseline, Week 8

  3. Change From Baseline in Calcium-Phosphorus Product at Week 8

    Missing Week 8 data were imputed by LOCF method.

    Time frame: Baseline, Week 8

  4. Change From Baseline in Intact Parathyroid Hormone (Ipth) Level at Week 8

    Missing Week 8 data were imputed by LOCF method.

    Time frame: Baseline, Week 8

  5. Percentage of Participants Reaching the Target Serum Phosphorus Level (4.6 mg/dL [1.49 mmol/L]) at Week 8

    Missing Week 8 data were imputed by LOCF method.

    Time frame: Week 8

  6. Change From Baseline in Serum Phosphorus Level at Week 4

    Missing Week 4 data were imputed by LOCF method.

    Time frame: Baseline, Week 4

  7. Number of Participants With Treatment Emergent Adverse Event

    Any untoward medical occurrence in a participant who received investigational medicinal product (IMP) was considered an Adverse Event (AE) without regard to possibility of causal relationship with this treatment. Treatment-emergent adverse events (TEAEs) were defined as AEs that developed or worsened or became serious during TEAE period. On-treatment period was defined as the (time from the first dose of IMP to the last dose of IMP+3 days). A serious adverse event (SAE) was defined as any untoward medical occurrence that resulted in any of the following outcomes: death, life-threatening, required initial or prolonged in-patient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event. Any TEAE included participants with both serious and non-serious AEs.

    Time frame: From first dose of IMP to the last dose of IMP +3 days i.e. up to Day 59

  8. Number of Participants With Clinically Significant Laboratory Abnormalities: Hematological Parameters

    Criteria for potentially clinically significant abnormalities: * Hemoglobin: \<=115 g/L (Male\[M\]) or \<=95 g/L (Female \[F\]); \>=185 g/L (M) or \>=165 g/L (F); Decrease from baseline (DFB) \>=20 g/L * Hematocrit: \<=0.37 v/v (M) or \<=0.32 v/v (F); \>=0.55 v/v (M) or \>=0.5 v/v (F) * Red blood cells (RBC): \>=6 Tera/L * Platelets: \<100 Giga/L; \>=700 Giga/L * White blood cells (WBC): \<3.0 Giga/L (Non-Black \[NB\]) or \<2.0 Giga/L (Black \[B\]); \>=16.0 Giga/L * Neutrophils: \<1.5 Giga/L (NB) or \<1.0 Giga/L (B); \<1.0 Giga/L * Lymphocytes: \>4.0 Giga/L * Monocytes: \>0.7 Giga/L * Basophils: \>0.1 Giga/L * Eosinophils: \>0.5 Giga/L or \>upper limit of normal (ULN) (if ULN \>=0.5 Giga/L)

    Time frame: From first dose of IMP to the last dose of IMP +3 days i.e. up to Day 59

  9. Number of Participants With Clinically Significant Laboratory Abnormalities: Metabolic Parameters

    Criteria for potentially clinically significant abnormalities: * Glucose: \<=3.9 mmol/L and \< lower limits of normal (LLN); \>=11.1 mmol/L (unfasted \[unfas\]) or \>=7 mmol/L (fasted \[fas\]) * Triglycerides: \>=4.6 mmol/L * Albumin: \<= 25 g/L.

    Time frame: From first dose of IMP to the last dose of IMP +3 days i.e. up to Day 59

  10. Number of Participants With Clinically Significant Laboratory Abnormalities: Electrolytes

    Criteria for potentially clinically significant abnormalities: Sodium: \<=129 millimoles (mmol)/L; \>=160 mmol/L Potassium: \<3 mmol/L; \>=5.5 mmol/L Chloride: \<80 mmol/L; \>115 mmol/L.

    Time frame: From first dose of IMP to the last dose of IMP +3 days i.e. up to Day 59

  11. Number of Participants With Clinically Significant Laboratory Abnormalities: Renal Function Parameters

    Criteria for potentially clinically significant abnormalities: Creatinine: \>=150 micromol/L; \>=30% change from baseline, \>=100% change from baseline Creatinine clearance: \<15 mL/min; \>=15 to \<30 mL/min; \>=30 to \<60 mL/min; \>=60 to \<90 mL/min Blood urea nitrogen: \>=17 mmol/L Uric acid: \<120 micromol/L; \>408 micromol/L Glomular Filtration Rate (GFR): \< 15 mL/min/1.73m\^2, \>= 15 - \< 30 mL/min/1.73m\^2, \>= 30 - \< 60 mL/min/1.73m\^2, \>= 60 - \< 90 mL/min/1.73m\^2.

    Time frame: From first dose of IMP to the last dose of IMP +3 days i.e. up to Day 59

  12. Number of Participants With Clinically Significant Laboratory Abnormalities: Liver Function Parameters

    Criteria for potentially clinically significant abnormalities: Alanine Aminotransferase (ALT): \>3 ULN; \>5 ULN; \>10 ULN; Aspartate aminotransferase (AST): \>3 ULN.

    Time frame: From first dose of IMP to the last dose of IMP +3 days i.e. up to Day 59

  13. Number of Participants With Clinically Significant Vital Signs Abnormalities

    Criteria for potentially clinically significant vital sign abnormalities: Systolic blood pressure (SBP) supine: \<=95 millimeters of mercury (mmHg) and DFB \>=20 mmHg; \>=160 mmHg and increase from baseline (IFB) \>=20 mmHg Diastolic blood pressure (DBP) supine: \<=45 mmHg and DFB \>=10 mmHg; \>=110 mmHg and IFB \>=10 mmHg Heart rate (HR) supine: \<=50 beats per minute (bpm) and DFB \>=20 bpm; \>=120 bpm and IFB \>=20 bpm Weight: \>=5% DFB; \>=5% IFB.

    Time frame: From first dose of IMP to the last dose of IMP +3 days i.e. up to Day 59

07

Results

Posted Jul 28, 2020

Participant flow

Study was conducted at 38 centers in China. A total of 482 participants were screened between 07 June 2017 \& 30 May 2019, of which 280 participants were screen failures. Screen failures were mainly due to serum phosphorus level greater than or equal to \>=5.5 milligrams per deciliter (mg/dL) (1.78 millimoles per litre \[mmol/L\]) at screening visit.

Participant flow — Overall Study
MilestonePlaceboRenvela
Started101101
Completed7480
Not completed2721
Withdrew: Adverse event93
Withdrew: Chronic kidney disease lead to dialysis1510
Withdrew: Other than specified above38

Outcome measures

PrimaryChange From Baseline in Serum Phosphorus at Week 8

Baseline of serum phosphorus value was the last serum phosphorus level obtained before the first double-blind investigational medicinal product (IMP) dosing. Missing Week 8 data were imputed by last observation carried forward \[LOCF\] method.

Time frame:
Baseline, Week 8
Reported as:
Median · mmol/L
Change From Baseline in Serum Phosphorus at Week 8
mmol/LPlaceboRenvela
Baseline2.090 (1.870 to 2.270)2.095 (1.870 to 2.400)
Change at Week 80.010 (-0.200 to 0.250)-0.200 (-0.490 to 0.020)
Statistical analysis
  • Placebo vs Renvela · Wilcoxon rank sum test · p = <0.0001 (Threshold for statistical significance at 0.05.) · Median difference (renvela - placebo): -0.210Renvela Vs. Placebo
SecondaryChange From Baseline in Total Cholesterol at Week 8

Missing Week 8 data were imputed by LOCF method.

Time frame:
Baseline, Week 8
Reported as:
Median · mmol/L
Change From Baseline in Total Cholesterol at Week 8
mmol/LPlaceboRenvela
Change From Baseline in Total Cholesterol at Week 8-0.115 (-1.82 to 1.54)-0.830 (-4.45 to 0.74)
SecondaryChange From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 8

Missing Week 8 data were imputed by LOCF method.

Time frame:
Baseline, Week 8
Reported as:
Median · mmol/L
Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 8
mmol/LPlaceboRenvela
Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 8-0.030 (-1.61 to 1.30)-0.830 (-3.31 to 0.51)
SecondaryChange From Baseline in Calcium-Phosphorus Product at Week 8

Missing Week 8 data were imputed by LOCF method.

Time frame:
Baseline, Week 8
Reported as:
Median · mmol^2/L^2
Change From Baseline in Calcium-Phosphorus Product at Week 8
mmol^2/L^2PlaceboRenvela
Change From Baseline in Calcium-Phosphorus Product at Week 80.0200 (-2.648 to 2.936)-0.4960 (-2.592 to 2.696)
SecondaryChange From Baseline in Intact Parathyroid Hormone (Ipth) Level at Week 8

Missing Week 8 data were imputed by LOCF method.

Time frame:
Baseline, Week 8
Reported as:
Median · nanogram per liter (ng/L)
Change From Baseline in Intact Parathyroid Hormone (Ipth) Level at Week 8
nanogram per liter (ng/L)PlaceboRenvela
Change From Baseline in Intact Parathyroid Hormone (Ipth) Level at Week 87.2380 (-298.732 to 573.306)0.0000 (-370.172 to 327.966)
SecondaryPercentage of Participants Reaching the Target Serum Phosphorus Level (4.6 mg/dL [1.49 mmol/L]) at Week 8

Missing Week 8 data were imputed by LOCF method.

Time frame:
Week 8
Reported as:
Number · percentage of participants
Percentage of Participants Reaching the Target Serum Phosphorus Level (4.6 mg/dL [1.49 mmol/L]) at Week 8
percentage of participantsPlaceboRenvela
Percentage of Participants Reaching the Target Serum Phosphorus Level (4.6 mg/dL [1.49 mmol/L]) at Week 86.615.5
SecondaryChange From Baseline in Serum Phosphorus Level at Week 4

Missing Week 4 data were imputed by LOCF method.

Time frame:
Baseline, Week 4
Reported as:
Median · mmol/L
Change From Baseline in Serum Phosphorus Level at Week 4
mmol/LPlaceboRenvela
Change From Baseline in Serum Phosphorus Level at Week 4-0.020 (-1.56 to 2.42)-0.240 (-1.03 to 1.39)
SecondaryNumber of Participants With Treatment Emergent Adverse Event

Any untoward medical occurrence in a participant who received investigational medicinal product (IMP) was considered an Adverse Event (AE) without regard to possibility of causal relationship with this treatment. Treatment-emergent adverse events (TEAEs) were defined as AEs that developed or worsened or became serious during TEAE period. On-treatment period was defined as the (time from the first dose of IMP to the last dose of IMP+3 days). A serious adverse event (SAE) was defined as any untoward medical occurrence that resulted in any of the following outcomes: death, life-threatening, required initial or prolonged in-patient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event. Any TEAE included participants with both serious and non-serious AEs.

Time frame:
From first dose of IMP to the last dose of IMP +3 days i.e. up to Day 59
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Event
ParticipantsPlaceboRenvela
Any TEAE8683
Any Treatment emergent SAE3126
any TEAE leading to permanent discontinuation2112
SecondaryNumber of Participants With Clinically Significant Laboratory Abnormalities: Hematological Parameters

Criteria for potentially clinically significant abnormalities: * Hemoglobin: \<=115 g/L (Male\[M\]) or \<=95 g/L (Female \[F\]); \>=185 g/L (M) or \>=165 g/L (F); Decrease from baseline (DFB) \>=20 g/L * Hematocrit: \<=0.37 v/v (M) or \<=0.32 v/v (F); \>=0.55 v/v (M) or \>=0.5 v/v (F) * Red blood cells (RBC): \>=6 Tera/L * Platelets: \<100 Giga/L; \>=700 Giga/L * White blood cells (WBC): \<3.0 Giga/L (Non-Black \[NB\]) or \<2.0 Giga/L (Black \[B\]); \>=16.0 Giga/L * Neutrophils: \<1.5 Giga/L (NB) or \<1.0 Giga/L (B); \<1.0 Giga/L * Lymphocytes: \>4.0 Giga/L * Monocytes: \>0.7 Giga/L * Basophils: \>0.1 Giga/L * Eosinophils: \>0.5 Giga/L or \>upper limit of normal (ULN) (if ULN \>=0.5 Giga/L)

Time frame:
From first dose of IMP to the last dose of IMP +3 days i.e. up to Day 59
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Laboratory Abnormalities: Hematological Parameters
ParticipantsPlaceboRenvela
Hemoglobin <=115 g/L (M) or <=95 g/L (F)5954
Hemoglobin >=185 g/L (M) or >=165 g/L (F)00
Hemoglobin DFB >=20 g/L96
Hematocrit <=0.37 v/v (M) or <=0.32 v/v (F)6867
Hematocrit >0.55 v/v (M) or >=0.5 v/v (F)00
RBC >=6 Tera/L01
Platelets <100 Giga/L34
Platelets >=700 Giga/L00
WBC <3.0 Giga/L (NB) or <2.0 Giga/L (B)20
WBC >=16.0 Giga/L00
Neutrophils <1.5 Giga/L (NB) or <1.0 Giga/L (B)00
Lymphocytes >4 Giga/L00
Monocytes >0.7 Giga/L00
Basophils >0.1 Giga/L00
Eosinophils >0.5 Giga/L or >ULN (ULN >=0.5 Giga/L)46
SecondaryNumber of Participants With Clinically Significant Laboratory Abnormalities: Metabolic Parameters

Criteria for potentially clinically significant abnormalities: * Glucose: \<=3.9 mmol/L and \< lower limits of normal (LLN); \>=11.1 mmol/L (unfasted \[unfas\]) or \>=7 mmol/L (fasted \[fas\]) * Triglycerides: \>=4.6 mmol/L * Albumin: \<= 25 g/L.

Time frame:
From first dose of IMP to the last dose of IMP +3 days i.e. up to Day 59
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Laboratory Abnormalities: Metabolic Parameters
ParticipantsPlaceboRenvela
Triglycerides: >=4.6 mmol/L02
Glucose: =< 3.9 mmol/L and < LLN11
Glucose: >=11.1 mmol/L(unfas); >=7 mmol/L(fas)56
Albumin: <= 25 g/L10
SecondaryNumber of Participants With Clinically Significant Laboratory Abnormalities: Electrolytes

Criteria for potentially clinically significant abnormalities: Sodium: \<=129 millimoles (mmol)/L; \>=160 mmol/L Potassium: \<3 mmol/L; \>=5.5 mmol/L Chloride: \<80 mmol/L; \>115 mmol/L.

Time frame:
From first dose of IMP to the last dose of IMP +3 days i.e. up to Day 59
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Laboratory Abnormalities: Electrolytes
ParticipantsPlaceboRenvela
Sodium <=129 mmol/L13
Sodium >=160 mmol/L00
Potassium <3 mmol/L00
Potassium >=5.5 mmol/L3646
Chloride <80 mmol/L02
Chloride >115 mmol/L00
SecondaryNumber of Participants With Clinically Significant Laboratory Abnormalities: Renal Function Parameters

Criteria for potentially clinically significant abnormalities: Creatinine: \>=150 micromol/L; \>=30% change from baseline, \>=100% change from baseline Creatinine clearance: \<15 mL/min; \>=15 to \<30 mL/min; \>=30 to \<60 mL/min; \>=60 to \<90 mL/min Blood urea nitrogen: \>=17 mmol/L Uric acid: \<120 micromol/L; \>408 micromol/L Glomular Filtration Rate (GFR): \< 15 mL/min/1.73m\^2, \>= 15 - \< 30 mL/min/1.73m\^2, \>= 30 - \< 60 mL/min/1.73m\^2, \>= 60 - \< 90 mL/min/1.73m\^2.

Time frame:
From first dose of IMP to the last dose of IMP +3 days i.e. up to Day 59
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Laboratory Abnormalities: Renal Function Parameters
ParticipantsPlaceboRenvela
Creatinine >=150 micromol/L8489
Creatinine >=30% change from baseline1533
Creatinine >=100% change from baseline33
Creatinine Clearance <15 mL/min7781
Creatinine clearance >=15 to <30 mL/min68
Creatinine clearance >=30 to <60 mL/min10
Creatinine clearance >=60 to <90 mL/min00
Blood Urea Nitrogen >=17 mmol/L7783
Uric acid <120 micromol/L00
Uric acid >408 micromol/L5667
GFR < 15 mL/min/1.73m^28286
GFR >= 15 - < 30 mL/min/1.73m^223
GFR >= 30 - < 60 mL/min/1.73m^200
GFR >= 60 - < 90 mL/min/1.73m^200
SecondaryNumber of Participants With Clinically Significant Laboratory Abnormalities: Liver Function Parameters

Criteria for potentially clinically significant abnormalities: Alanine Aminotransferase (ALT): \>3 ULN; \>5 ULN; \>10 ULN; Aspartate aminotransferase (AST): \>3 ULN.

Time frame:
From first dose of IMP to the last dose of IMP +3 days i.e. up to Day 59
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Laboratory Abnormalities: Liver Function Parameters
ParticipantsPlaceboRenvela
ALT >3 ULN10
ALT >5 ULN10
ALT >10 ULN00
AST >3 ULN00
SecondaryNumber of Participants With Clinically Significant Vital Signs Abnormalities

Criteria for potentially clinically significant vital sign abnormalities: Systolic blood pressure (SBP) supine: \<=95 millimeters of mercury (mmHg) and DFB \>=20 mmHg; \>=160 mmHg and increase from baseline (IFB) \>=20 mmHg Diastolic blood pressure (DBP) supine: \<=45 mmHg and DFB \>=10 mmHg; \>=110 mmHg and IFB \>=10 mmHg Heart rate (HR) supine: \<=50 beats per minute (bpm) and DFB \>=20 bpm; \>=120 bpm and IFB \>=20 bpm Weight: \>=5% DFB; \>=5% IFB.

Time frame:
From first dose of IMP to the last dose of IMP +3 days i.e. up to Day 59
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Vital Signs Abnormalities
ParticipantsPlaceboRenvela
SBP (supine) <=95 mmHg and DFB >=20 mmHg00
SBP (supine) >=160 mmHg and IFB >=20 mmHg1712
DBP (supine) <=45 mmHg and DFB >=10 mmHg00
DBP (supine) >=110 mmHg and IFB >=10 mmHg23
HR (supine) <=50 bpm and DFB >= 20 bpm00
HR (supine) >=120 bpm and IFB >=20 bpm00
Weight >=5% DFB127
Weight >=5% IFB149

Adverse events

Collected over Reported AEs are TEAEs that is AEs that developed/worsened or became serious during the TEAE period (time from the first dose of IMP to the last dose of IMP+3 days i.e. Day 59).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/101 (0%)31/101 (30.7%)52/101 (51.5%)
Renvela0/101 (0%)26/101 (25.7%)60/101 (59.4%)
Most frequent serious events
Showing 10 of 29
Most frequent serious events
EventPlaceboRenvela
Chronic Kidney DiseaseRenal and urinary disorders13/1018/101
End Stage Renal DiseaseRenal and urinary disorders7/1019/101
AzotaemiaRenal and urinary disorders4/1011/101
Lung InfectionInfections and infestations2/1012/101
HyperkalaemiaMetabolism and nutrition disorders2/1012/101
AnaemiaBlood and lymphatic system disorders1/1010/101
Angina PectorisCardiac disorders1/1010/101
Cardiac FailureCardiac disorders1/1011/101
Cardiac Failure AcuteCardiac disorders1/1010/101
CataractEye disorders0/1011/101
Most frequent other events
Showing 10 of 11
Most frequent other events
EventPlaceboRenvela
HyperkalaemiaMetabolism and nutrition disorders18/10125/101
NauseaGastrointestinal disorders15/10110/101
Oedema PeripheralGeneral disorders9/10114/101
VomitingGastrointestinal disorders13/10112/101
Decreased AppetiteMetabolism and nutrition disorders11/1014/101
Upper Respiratory Tract InfectionInfections and infestations9/1018/101
DiarrhoeaGastrointestinal disorders8/1015/101
HypocalcaemiaMetabolism and nutrition disorders8/1013/101
ConstipationGastrointestinal disorders5/1017/101
Metabolic AcidosisMetabolism and nutrition disorders7/1014/101

Baseline characteristics

Analysis was performed on randomized participants.

Age, Continuous
Age, Continuous(years)PlaceboRenvelaTotal
Mean50.9 ± 12.450.6 ± 13.550.7 ± 12.9
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboRenvelaTotal
Female464894
Male5553108
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboRenvelaTotal
American Indian or Alaska Native000
Asian101101202
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported000
08

Study locations

38 sites
  • Investigational Site Number 1560003
    Beijing, 100034, China
  • Investigational Site Number 1560026
    Cangzhou, 061000, China
  • Investigational Site Number 1560015
    Changchun, 130021, China
  • Investigational Site Number 1560011
    Changsha, 410011, China
  • Investigational Site Number 1560030
    Chongqing, 400038, China
  • Investigational Site Number 1560019
    Dalian, 116011, China
  • Investigational Site Number 1560013
    Fuzhou, 350005, China
  • Investigational Site Number 1560001
    Guangzhou, 510080, China
  • Investigational Site Number 1560027
    Guangzhou, 510120, China
  • Investigational Site Number 1560037
    Guilin, China
  • Investigational Site Number 1560031
    Haikou, 570311, China
  • Investigational Site Number 1560036
    Hengyang, 421001, China
  • Investigational Site Number 1560039
    Hengyang, 421001, China
  • Investigational Site Number 1560023
    Hohhot, 010050, China
  • Investigational Site Number 1560033
    Kunming, China
  • Investigational Site Number 1560034
    Kunming, China
  • Investigational Site Number 1560006
    Lanzhou, 730030, China
  • Investigational Site Number 1560004
    Nanchang, 330006, China
  • Investigational Site Number 1560005
    Nanchang, 330006, China
  • Investigational Site Number 1560032
    Nanchang, 330006, China
  • Investigational Site Number 1560017
    Nanjing, 210011, China
  • Investigational Site Number 1560029
    Nanning, China
  • Investigational Site Number 1560028
    Ningbo, China
  • Investigational Site Number 1560002
    Shanghai, 200025, China
  • Investigational Site Number 1560007
    Shanghai, 200072, China
  • Investigational Site Number 1560021
    Shenyang, 110004, China
  • Investigational Site Number 1560038
    Shenyang, 110016, China
  • Investigational Site Number 1560025
    Shijiazhuang, 050000, China
  • Investigational Site Number 1560022
    Taiyuan, 030001, China
  • Investigational Site Number 1560012
    Tianjin, 300052, China
  • Investigational Site Number 1560014
    Tianjin, 300121, China
  • Investigational Site Number 1560010
    Wuhan, 430030, China
  • Investigational Site Number 1560008
    Xi'An, 710061, China
  • Investigational Site Number 1560020
    Xiamen, 361003, China
  • Investigational Site Number 1560018
    Xiamen, 361004, China
  • Investigational Site Number 1560035
    Xuzhou, 221002, China
  • Investigational Site Number 1560024
    Yinchuan, 750004, China
  • Investigational Site Number 1560016
    Zhanjiang, 524001, China
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2017 to primary completion in Aug 2019, 26 months.

Results were first posted in Jul 2020, 11 months after primary completion.

Of 21 phase 3 interventional studies under Hyperphosphatemia, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 22. This study's 26 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 20, 2016
First posted
Dec 22, 2016
StartActual
Jun 7, 2017
Primary completionActual
Aug 16, 2019
CompletionActual
Aug 16, 2019
Results first posted
Jul 28, 2020
Last update
Mar 25, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 25, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03001011
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Dec 22, 2016
Start date
Jun 7, 2017
Primary completion
Aug 16, 2019
Completion
Aug 16, 2019
Results posted
Jul 28, 2020
Last update
Mar 25, 2022

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sevelamer

Start the discussion